Hiệu quả của thuốc Midazolam đường tiêm tĩnh mạch cho bệnh nhi trước siêu âm doppler tim tại Bệnh viện Nhi Trung ương

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Thị Thanh Lê, Văn Tuyến Lê, Thanh Huyền Ngô, Thị Hồng Phúc Nguyễn, Thị Thuận Nguyễn, Thị Vân Anh Nguyễn, Thị Yến Phạm, Thu Hằng Trần, Thị Linh Nhâm Ứng, Thị Vân Vũ

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Khoa học Điều dưỡng, 2023

Mô tả vật lý: tr.136

Bộ sưu tập: Metadata

ID: 347343

Thêm vào giỏ Liên kết toàn văn

Mục tiêu: Đánh giá hiệu quả của thuốc Midazolam đường tiêm tĩnh mạch cho bệnh nhi trước siêu âm Doppler tim tại khoa Khám bệnh tim mạch và Điện sinh lý, Trung tâm Tim mạch, Bệnh viện Nhi Trung ương. Đối tượng và phương pháp nghiên cứu: Thiết kế nghiên cứu mô tả cắt ngang đã được tiến hành trong thời gian từ 01/12/2022 đến 31/3/2023 với cỡ mẫu thuận tiện trên 312 bệnh nhi có chỉ định sử dụng Midazolam đường tiêm tĩnh mạch trước siêu âm Doppler tim. Kết quả: Tuổi trung vị và cân nặng trung vị của bệnh nhi trong nhóm nghiên cứu lần lượt là 12 tháng (IQR = 15,4) và 8 kg (IQR = 3,6). Liều tiêm trung vị là 0.19 mg/kg/lần (IQR = 0,1). Chỉ có 13 bệnh nhi trong 312 bệnh nhi (4,2%) được chỉ định liều tiêm thứ hai để hoàn thành siêu âm Doppler tim với liều trung vị lần 2 là 0,125mg/kg/lần (IQR = 0,06). Thuốc Midazolam có tác dụng an thần trong thời gian trung vị là 5 phút (IQR = 3,2). Tất cả các bệnh nhi trong nghiên cứu (n = 312) sau sử dụng thuốc Midazolam không có các dấu hiệu shock phản vệ, tím tái, co giật, suy hô hấp hoặc ngừng thở. Kết luận: Sử dụng thuốc Midazolam đường tiêm tĩnh mạch có hiệu quả an thần cho bệnh nhi trước siêu âm Doppler tim.Objective: Initial evaluation of the effectiveness and side effects of intravenous midazolam for children undergoing echocardiography at the Department of Outclinic Cardiac Exam and Diagnosis, Heart Center, Vietnam National Children’s Hospital. Subjects and methods: From Decber 2022 to March 2023, a prospective, cross-sectional study using a convenience sample was conducted to examine the effectiveness of of intravenous midazolam on 312 children undergoing echocardiography at Department of Outclinic Cardiac Exam and Diagnosis , Vietnam National Children’s Hospital. Results: The median age and median weight of children in the study were 12 months (IQR = 15.4) and 8 kg(IQR = 3.6), respectively. Only 13 children (4.2%) needed the second dose of Midazolam to complete the echocardiography with a lower dose of of 0.125mg/kg/time (IQR = 0.06) compared to the first one. The median duration of the medication in effect was 5 minutes (IQR = 3.2). There were no children experiencing with signs of anaphylaxis, cyanosis, convulsions, respiratory failure or apnea. Conclusion: It is likely that the use of intravenous Midazolam for children is effective in promoting their collaboration with healthcare staff while minimising side effects during echocardiography procedures

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR